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Abstract
Objective—There is limited evidence on whether growing mobile phone availability in sub-
Saharan Africa can be used to promote high adherence to antiretroviral therapy (ART). This study
tested the efficacy of short message service (SMS) reminders on adherence to ART among
patients attending a rural clinic in Kenya.
Design—A randomized controlled trial of four SMS reminder interventions with 48 weeks of
follow-up.
Methods—Four hundred and thirty-one adult patients who had initiated ART within 3 months
were enrolled and randomly assigned to a control group or one of the four intervention groups.
Participants in the intervention groups received SMS reminders that were either short or long and
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sent at a daily or weekly frequency. Adherence was measured using the medication event
monitoring system. The primary outcome was whether adherence exceeded 90% during each 12-
week period of analysis and the 48-week study period. The secondary outcome was whether there
were treatment interruptions lasting at least 48 h.
Results—In intention-to-treat analysis, 53% of participants receiving weekly SMS reminders
achieved adherence of at least 90% during the 48 weeks of the study, compared with 40% of
participants in the control group (P=0.03). Participants in groups receiving weekly reminders were
also significantly less likely to experience treatment interruptions exceeding 48 h during the 48-
week follow-up period than participants in the control group (81 vs. 90%, P = 0.03).
Conclusion—These results suggest that SMS reminders may be an important tool to achieve
optimal treatment response in resource-limited settings.
Keywords
adherence; antiretroviral therapy; HIV/AIDS; mobile phones; randomized controlled trial; sub-
Saharan Africa; text message reminders
Introduction
Although antiretroviral therapy (ART) has dramatically reduced morbidity and mortality for
people living with HIV/AIDS, incomplete treatment adherence is the major cause of
treatment failure, development of drug resistance, HIV disease progression, and death [1–5].
Initial concerns about poor adherence and widespread drug resistance in resource-limited
settings have not been realized [6–8]. Many studies indicate that adherence in resource-
limited settings is at least as good, if not better than in North America [9–12]. However,
evidence from large-scale treatment programs has been lacking, and some studies have
found that adherence among individuals in sub-Saharan Africa declines over time [13,14].
Given the prohibitive cost of second-line therapy, successful adherence support
interventions may be cost saving [11,12].
There is no consensus about the best approach to improve adherence in resource-limited
settings [15]. Significant challenges include the large numbers of individuals on ART who
are residentially dispersed and who face structural and economic constraints to sustained
treatment access [9]. However, many resource-limited settings have well developed cellular
telecommunication networks and mobile phone ownership worldwide has grown
dramatically from 1 billion in 2002 to 4.1 billion in 2008 [16]. Mobile phones have been
shown to improve chronic disease management in developed countries and have been
proposed as a potential strategy to support ART adherence in developing countries [17–19].
Reminder devices, however, have shown mixed results and few data are available for
resource-limited settings [20–22]. Encouragingly, a study conducted in Mombasa, Kenya,
found that alarm devices significantly improved non-ART medication adherence rates
among women attending sexually transmitted disease and family planning clinics [23].
Methods
Participants and setting
The study was conducted at the Chulaimbo Rural Health Center (CRHC) in Nyanza
Province, Kenya. CRHC is a government-run health facility that has hosted an HIV clinic
run by the Academic Model Providing Access to Healthcare (AMPATH) since 2005. At the
time of the study, 45% of study participant households reported cell phone ownership and
97% resided within cell phone network coverage.
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All participants gave informed consent to participation in the study, which was approved by
the Institutional Research Ethics Committee of Moi University and the human subjects
committee of Georgetown University. Study participants were recruited at AMPATH’s HIV
clinic at CRHC. Recruitment began on 17 June 2007. Patients older than 18 years of age
who had initiated ART less than 3 months prior to enrollment were eligible for the study.
Eligible patients were informed about the study and then asked for consent in one of three
languages (English, Dholuo, and Kiswahili). All participants were informed that they would
receive a mobile phone and that some would be randomly selected to receive daily or
weekly text messages encouraging adherence to ART. They were also informed that one of
their medications would be dispensed in bottles with electronic caps monitoring daily usage.
Interventions and study design
Participants were provided with a Nokia mobile phone and told that they could use it as they
desired. The study did not restrict enrollment to participants who already owned a phone to
avoid selection biases from preexisting phone ownership. Participants were referred to the
pharmacy, wherein one of their three antiretroviral medications (in all but one case
lamivudine) was transferred to a bottle with a medication event monitoring system (MEMS)
cap by the pharmacy staff. The phone number and MEMS cap numbers of participants were
recorded by study staff.
Participants were randomly assigned to one of four intervention groups or to the control
group that would receive no text messages. One-third of the sample was allocated to the
control group, and the remaining two-thirds of the sample were allocated evenly to each of
the four intervention groups. The randomization schedule was prepared in advance of
enrollment by the investigators. A sequence of random numbers between 0 and 1 were
generated, and four equal intervals between 0 and 2/3 corresponded to the four intervention
groups, whereas the value interval from 2/3 to 1 corresponded to the control group.
The four text message interventions were chosen to address different barriers to adherence
such as forgetfulness and lack of social support [24,25]. Short messages were meant to serve
as a simple reminder to take medications, whereas long messages were meant to provide
additional support. Daily messages were close to the frequency of medication usage,
whereas weekly messages were meant to avoid the possibility that very frequent text
messages would be habituating. The content of each type of message is listed in Table 1.
The message content was developed after extensive consultation with clinic staff. Correct
phone use and comprehension of the message in English, Dholou, or Kiswahili was
confirmed during a basic 15-min training session. All messages were less than 160
characters and did not specify HIV or ART in order to maintain confidentiality of HIV
status. Participants were asked to specify their preferred language. Messages were sent
automatically initially by a commercial service provider (Zunguka) based in Nairobi and
later from Cardboard-Fish.com. The service sent ‘one-way’ messages to which respondents
could not respond. Messages were sent at 12 p.m., rather than twice daily (during dosing
times) to avoid excess reliance on the accuracy of the short message service (SMS) software.
Follow-up
Participants were expected to return to the clinic once a month as per AMPATH’s standard
procedures. MEMS caps were scanned monthly by study staff in the pharmacy.
The study provided regular assistance to participants in the intervention and control groups
owing to poor access to electricity and household financial constraints. As many participants
needed to charge their phones at fee-based ‘charging stations’ in nearby market centers, the
study provided 80 Kenya Shillings (approximately 1 US$) at every monthly visit. In
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addition, as the subscriber identity module (SIM) cards in phones would expire if phone
credit was not added regularly, 50 Kenya Shillings of phone credit was added to
participants’ phones every 2 months.
Participants were required to show their study-provided phone to the study staff during their
clinic visit. Participants who reported having lost their phones were not provided with a
replacement phone. To confirm the fidelity of the interventions, each of the messages were
sent on a daily or weekly basis to a separate phone maintained by the study supervisor to
ensure server functioning. Functionality of each participant’s phone was checked during
each visit.
Sample sizes
The study was designed to have 90% power to detect an impact of 15% in the fraction of
patients with adherence of at least 90% (assuming a no intervention median adherence level
of 90%), using a two-tailed test of significance at the 5% level.
The study population consisted of all participants enrolled between June 2007 and August
2008. SMS reminders were sent to intervention groups until 31 December 2008. We
restricted analyses to participants who were enrolled before 31 January 2008, the date by
which a 48-week follow-up was possible.
Medication event monitoring system use and data management
Several adjustments were made to the MEMS data to address variation in regimen and
MEMS cap use. First, refill MEMS events were censored. Second, many patients
experienced a clinic-driven regimen change to either fixed-dose combination of zidovudine/
lamivudine or fixed-dose combination of stavudine/lamivudine/ nevirapine during the first
half of 2008. These participants received the new medication in the MEMS bottle, but were
instructed to complete existing doses, which were transferred to an envelope. The number of
days of the remaining medication was recorded and censored.
MEMS adherence was calculated as the number of actual bottle openings divided by the
number of prescribed bottle openings for the period. Because all patients were prescribed
twice-daily ART, we set the maximum number of daily openings equal to two so that
MEMS adherence was not inflated by extra cap openings. Our primary outcome was a
binary indicator of whether the patient had adherence of at least 90% during each 12-week
period of analysis. As treatment interruptions are an important predictor of virologic failure
on nonnucleoside reverse transcriptase inhibitor therapy, our secondary outcome was a
binary indicator of whether patients had a treatment interruption exceeding 48 h during each
period of analysis [26]. An interruption was defined as having occurred if the time between
two consecutive MEMS openings exceeded 48 h.
Statistical analysis
We conducted an ‘inside the table’ analysis of our factorial research design. Differences in
the primary and secondary outcomes between each of the intervention groups and the
control group were compared using the χ2 -test for each 12-week period of observation (1 –
12, 13–24, 25–36, and 37–48 weeks), as well as the full 48-week follow-up period. Two
levels of analysis were conducted: a ‘summary analysis’ in which we compared the effects
of the daily, weekly, short and long reminders to the control group and a ‘subgroup analysis’
in which we compared each of the four intervention arms to the control group.
Our primary analysis was performed on an intention-to-treat basis. Individuals who
discontinued therapy or who were lost to follow-up were classified as nonadherent for the
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relevant observation period; they were coded as not having achieved adherence of at least
90% and as having experienced a treatment interruption exceeding 48 h. Our secondary
analysis was per-protocol, which compared adherence for participants retained in care for
each 12-week period of enrollment in the study and over the entire 48 weeks. In this
analysis, participants lost to follow-up during a given period were not included in the
analysis for that period. All analyses were conducted with STATA version 10.0 (StataCorp,
College Station, Texas, USA).
Results
Characteristics of the study population
Seven hundred and thirty-five patients were approached and 720 (97.9%) were enrolled
(Fig. 1). Our analyses are restricted to the 431 participants who were enrolled before 31
January 2008. A total of three participants had faulty MEMS caps and were excluded from
the analysis because of failure to reconstruct their MEMS data, resulting in an analytical
sample of 428 participants.
Among participants included in the analyses, 139 were in the control group, 70 in the short
daily reminders group, 72 in the long daily reminders group, 73 in the short weekly
reminders group, and 74 in the long weekly reminders group. The most common
antiretroviral medications provided at enrollment were lamivudine (99.8%), nevirapine
(88%), and zidovudine (64%). There is no difference across the control and each of the
intervention groups in the likelihood of switching regimens during the study χ2 -test,
P=0.76).
Table 2 shows that at baseline, most participants’ characteristics such as age, sex, religion,
ethnicity, marital status, and education were distributed similarly across the five groups in
the analytical sample. The only characteristic in -which there were significant differences
between groups -was residence in a home -with an iron roof (P=0.04). In addition, Table 2
shows that the analytical sample of 428 study participants -was not significantly different
from the entire sample of 720 participants -who -were enrolled in the study.
Retention of participants
Participants in the study were defined as lost to follow-up if more than 90 days had elapsed
after their last recorded MEMS opening. Sixty-nine participants, or 16% of the original
sample, were lost to follow-up as of 31 December 2008. This is consistent -with typical loss
to follow-up rates in similar programs [27,28]. The percentage of participants lost to follow-
up by group -was as follows: control group (14.4%), short daily reminders group (18.6%),
long daily reminders group (16.7%), short weekly reminders group (22%), and long -weekly
reminders group (10.8%). There was no significant difference in the rate of loss to follow-up
across the control and each of the four intervention groups (P=0.48).
Fidelity of intervention
A total of 69 participants lost their phones and 51 changed phone numbers during the course
of the study (this was usually due to patients’ opting to use their original SIM card and
phone number). The likelihood of losing the phone or changing phone numbers was not
significantly different across five groups (lost phones, χ2 -test, P = 0.60; changed number,
χ2 -test, P = 0.62). Twenty-five participants with a malfunctioning MEMS caps or with a
lost MEMS cap were provided with a replacement cap for their medications. There were no
differences in the likelihood of MEMS cap replacement (χ2 -test, P = 0.59).
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Adherence in the control group
Overall adherence for participants in the control group retained in care for 48 weeks was
75.8% and declined over the follow-up period. Table 3 shows that the fraction of
participants in the control group achieving adherence of at least 90% was 60% in weeks 1 –
12 and declined to 46% in weeks 37–48 (χ2 = 7.36, P = 0.007). In addition, 90% of the
control group experienced at least one treatment interruption exceeding 48 h (Table 5). The
percentage of participants with treatment interruptions also rose over time, from 40% in
weeks 1 – 12 to 58% in weeks 37–48 (P= 0.001).
Intervention effects on at least 90% adherence
Intention-to-treat analysis (daily and weekly reminders)—Table 3 describes the
percentage of participants achieving adherence of at least 90% for each group in weeks 1 –
12, 13–24, 25–36, 37–48, and 0–48. The top panel shows the summary results, whereas the
bottom panel shows the four intervention groups’ results. The fraction of participants with
adherence of at least 90% in the two groups receiving weekly reminders was significantly
higher than the control group (53 vs. 40%, P = 0.03). The fraction of participants with
adherence of at least 90% was not significantly greater for those receiving daily reminders
than the control group (41 vs. 40%, P = 0.92).
Intention-to-treat analysis (short and long reminders)—Adherence of participants
in the two groups receiving short or long reminders was similar to the control group in all
four quarters of the study. Over 48 weeks, the fraction of participants achieving adherence
of at least 90% was 47% in the two groups that received long reminders, compared with
40% in the control group (P=0.24). Similarly, the two groups receiving short reminders
achieved adherence of at least 90% at rates that were not significantly higher than the
control group (47 vs. 40%, P=0.24).
Per-protocol analysis (daily and weekly reminders)—Among participants who
were retained in care at 48 weeks, the fraction who achieved at least 90% adherence was
63% for the group that received weekly reminders (Table 4). This is significantly higher
than the control group (63 vs. 47%, P=0.01). The subgroup analysis suggests that this result
is largely driven by the group receiving short weekly reminders and the control group (68
vs. 47%, P=0.01). However, we acknowledge that lower retention in this group may have
impacted the adherence estimate. On the contrary, the group receiving long weekly
reminders was not significantly more adherent than the control group (P=0.12). Participants
in the intervention groups receiving daily messages were not more likely to be adherent (50
vs. 47%, P= 0.70).
Per-protocol analysis (short and long reminders)—The two groups receiving short
reminders and retained in care for 48 weeks were marginally more likely to be adherent than
the control group (59 vs. 47%, P= 0.07). The proportion achieving adherence of at least 90%
in the two groups receiving long reminders and retained in care in each observation period
was similar to the control group (55 vs. 47%, P=0.23).
Intervention effects on at least 48 h treatment interruptions
Intention-to-treat analysis (daily and weekly reminders)—Table 5 shows the
percentage of participants with at least one treatment interruption exceeding 48 h in each 12-
week period and over the entire 48 weeks. Participants lost to follow-up are classified as
having experienced a treatment interruption exceeding 48 h in this analysis. Participants in
the groups receiving weekly reminders were significantly less likely to experience at least
one treatment interruption over the entire follow-up period than participants in the control
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group (81 vs. 90%, P= 0.03). Participants receiving the daily messages were not
significantly less likely to report at least one treatment interruption greater than 48 h (86 vs.
90%, P=0.30).
Intention-to-treat analysis (short and long reminders)—Participants receiving the
long message were marginally less likely to report at least one interruption exceeding 48 h
over the 48-week period (83 vs. 90%, P=0.08). Participants receiving the short message
were as likely to report a treatment interruption as the controls group (84 vs. 90%, P=0.14).
Per-protocol analysis (daily and weekly reminders)—In Table 6, the fraction of
individuals with at least one treatment interruption exceeding 48 h and retained in care for
48 weeks in the two groups receiving weekly messages was significantly lower than the
control group (77 vs. 88%, P=0.02). The two groups receiving daily messages were as likely
as the control group to report a treatment interruption over 48 weeks (83 vs. 88%, P=0.24).
Per-protocol analysis (short and long reminders)—Participants retained in care at
the end of the 48-week study period and receiving either the short or long messages were
slightly less likely to report at least one treatment interruption over the 48-week period than
the control group (80 vs. 88%, P=0.08). The subgroup analysis suggests that this result is
driven by the intervention group that received weekly messages.
Discussion
Our data indicate that weekly SMS reminders increased the percentage of participants
achieving 90% adherence to ART by approximately 13–16% compared with no reminder.
These weekly reminders were also effective at reducing the frequency of treatment
interruptions, which have been shown to be an important cause of treatment resistant failure
in resource-limited settings [29]. Like other successful adherence interventions, the
intervention was effective in part by preventing the decline in adherence seen in the control
group from 60 to 46% achieving 90% adherence over 48 weeks [21,30,31]. Despite SMS
outages, phone loss, and a rural population, these results suggest that simple SMS
interventions could be an important strategy to sustaining optimal ART response. Preventing
adherence-related treatment failure is especially important in resource-limited settings
wherein second-line therapy is up to 17-fold more expensive than first-line therapy and often
unavailable [32].
Contrary to our expectations, adding words of encouragement in the longer text message
reminders was not more effective than either a short reminder or no reminder. Although
previous studies have shown benefit with individualized adherence tools [33,34], future cell
phone-based interventions should investigate how message form and content influence HIV
and other chronic disease-related behavior [35,36]. Message content must also take into
account the common practice of shared mobile phone use and the potential that individuals
will change phones numbers [37].
It is also interesting to note that weekly reminders improved adherence, whereas daily
reminders did not. Habituation, or the diminishing of a response to a frequently repeated
stimulus, may explain this finding. Daily messages might also have been considered
intrusive. Further research is needed to distinguish the mechanisms as to why the weekly
messages were most efficacious. Moreover, this study was not designed to link the sending
of a reminder with the actual time the individual opened the MEMS bottle. Wireless
technology has recently enabled real-time adherence monitoring, such that reminders can be
explicitly linked to missed dosages [38].
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The level of adherence we observed was less than what has been seen in early reports using
electronic monitoring [39]. This finding may reflect the fact that we censored all openings in
excess of two openings per day, which can lead to a falsely lower adherence estimate when
individuals take their evening dose just after midnight on the following day. Alternatively, it
is possible that population levels of adherence may be declining in rural resource-limited
settings as treatment access expands and there is less selection towards highly adherent
individuals starting ART [40,41].
There are several limitations to our study. We cannot positively distinguish whether the
intervention improved dose-taking behavior or simply improved use of the electronic
medication monitor. Individuals may remove several doses of ART from the MEMS bottle
at one time (also known as ‘pocket doses’) or simply cease using the monitor [42]. However,
there is no strong reason to believe that ‘pocket doses’ were taken at different rates by
intervention and control groups. Another limitation is that we do not have HIV-RNA
determinations and, therefore, cannot corroborate that the differences in adherence were
associated with differences in viral suppression. Finally, we measured adherence in only one
tablet and assume that this reflects adherence of the entire regimen.
The results of this study provide promising evidence that automated text message reminders
may improve adherence among patients initiating ART in resource-limited settings. This
strategy could be used for wide-scale improvement of adherence given the convenience and
low cost of delivering SMS. A single server can provide text messages to thousands of
patients over a wide geographic area and few human resources are needed beyond the initial
setup. This strategy could be a key component of comprehensive ART adherence support
[16]. However, due to the customary use of mobile phones by more than one individual in
some settings, cell phone interventions will need to continue to address issues of
confidentiality.
This study is among the first to present robust evidence of beneficial effects of mobile phone
technology for HIV/ AIDS care delivery, also known as mHealth. Although the potential for
mobile phones to make an impact on health has been popularized in the literature and lay
press, little evidence had been provided to support such claims [43,44]. Research is needed
to determine the reproducibility and generalizability of these findings. Moreover, beyond
adherence reminders, mobile phones may be used for appointment reminders, monitoring of
adherence and treatment side-effects, and other types of communication between patients
and healthcare workers in between clinic visits. Additional studies will be critical for
understanding the true benefits and best implementation strategies for mHealth in
developing countries.
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Fig. 1. Flowchart of randomized controlled trial
cART, combination antiretroviral therapy; MEMS, medication event monitoring system.
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Table 1
Content of short and long short message service reminders.
English Swahili Dholuo
Short reminder This is your reminder. Hili ni kumbukumbu lako. Ma en ote ma iparonigo.
Long reminder This is your reminder. Be strong
and courageous, we care about you.
Hili ni kumbukumbu lako.
Uwe na ujasiri, tunakujali.
Ma en ote ma iparonigo. Bed motegno
kendo bed gi chir, wageni.
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